Key result
Pharmacokinetic-pharmacodynamic modeling of beta-blockers identifies poor responders and guides dose optimization.
Why the study?
β-blockers have heterogeneous pharmacokinetic and pharmacodynamic properties that require extensive evaluation to optimize cardiovascular disease treatment outcomes.
Answers are grounded in this paper and cite their sources.
PK/PD modeling aids individualized β-blocker dosing in CVD; leaves open prospective outcome validation before practice change.
β-blockers play a central role in the treatment of the various main cardiovascular diseases, including hypertension, coronary artery disease and systolic heart failure. As a therapeutic class, β-blockers form a heterogeneous family that differs in their pharmacokinetic (PK) and pharmacodynamic (PD) properties, highlighting the relevance of the extensive evaluation of PK/PD properties of these agents in order to optimize the outcomes of the treatment of cardiovascular diseases. Preclinical and clinical studies using PK/PD models have been able to identify different factors associated with cardiovascular response of β-blockers, including age, pharmaceutical formulation and genetic polymorphism, among others. PK/PD modeling of β-blockers can also be attractive for the early detection of poor responders and the optimization of dose regimen in their different indications.
No takes yet. Share an insight, caveat, or question.
Höcht et al. (2016) conducted a review in Cardiovascular diseases. β-blockers was evaluated. Pharmacokinetic and pharmacodynamic modeling of β-blockers helps identify factors associated with cardiovascular response, enabling early detection of poor responders and dose optimization.
Synapse has enriched 10 related papers. Consider them for comparative context: